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Background: Consumption of sugar causes tooth decay, overweight and obesity related morbidities. This paper in
response to the Minister of Health’s request, provides estimates of the mortality, morbidity and health care costs
attributable to sugar consumption in Israel along with the effects of reducing sugar consumption.
Methods: Gender specific relative risks of many diseases from overweight (25 < =BMI < 30) and obesity (BMI > =30)
were applied to the national gender specific prevalence rates of overweight and obesity in order to calculate the
population attributable fraction (PAF) from overweight and obesity. National expenditure on these related diseases
was calculated by applying disease-specific data from a recent Canadian study to estimates of disease specific
general hospital expenditures in Israel. Disease specific costs attributable to overweight and obesity were estimated
from the product of these expenditures and PAF. In addition national costs of treating caries in persons under
18 years of age from sugar were calculated. Similar calculations were made to estimate the burden from sugar in
terms of mortality and hospital utilisation. A recent UK modelling study was used to estimate the effect of a
national program to reduce calorific consumption of sugar from 12.45 to 10% in 5 years.
Results: Conditions associated with overweight or obesity accounted annually for 6402 deaths (95% CI 3296–8760)
and 268,009 hospital days. Dental costs attributable to sugar consumption were 264 million NIS. In total, obesity,
overweight and sugar consumption accounted for 2449 million in direct treatment costs (0.21% of GDP), rising to
4027 million (0.35% of GDP) when indirect costs were included. A national program of reducing energy from sugar
consumption from 12.45 to 10% over 5 years is considered have a very feasible short-term goal. Even if the
program does not impose taxes on sugar consumption, this would save 778 million NIS as well as 1184 lives.
Conclusion: Sugar consumption causes a huge monetary and mortality burden. Estimates of potential decreases in
this burden justify the current prioritisation given by the health minister of creating and implementing a national
program to reduce sugar consumption, which is likely to be cost-saving (ie: averted treatment costs will exceed
intervention costs).
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The increasing prevalence of obesity, which has more than
doubled since 1980 [1] is an important public health prob-
lem that contributes to excess morbidity and, to a lesser
degree, increased mortality [2]. In 2000, the World Health
Organization (WHO) attributed 7–25% of total health
care costs worldwide [2] to obesity. In 2014, worldwide,
there were over 1.9 billion overweight (25 = <Body Mass
Index [BMI] < 30) in addition to more than 600 million
obese adults (BMI ≥ 30). Elevated BMI is associated with a
higher risk of many non-communicable diseases [1].
Overweight and obesity, as well as their related non-
communicable diseases, are largely preventable. It is ac-
knowledged that there exists a multiplicity of measures
to prevent overweight or obesity such as encouraging
physical activity [3], reducing alcohol intake [4] and re-
ducing daytime napping [5]. However, the fundamental
cause of overweight and obesity is an energy imbalance
between calories consumed and calories expended.
At the individual level, people can
a) Limit their energy intake from total fats and sugars
[1];
b) Increase their consumption of fruit, vegetables,
legumes, whole grains and nuts [1]
c) Engage in regular physical activity [1, 3].
Individual responsibility can only have its full effect
where people have access to a healthy lifestyle. There-
fore, at the societal level it is important to undertake
policies that support individuals to engage in regular
physical activity and make healthier dietary choices [1].
Consuming too much sugar and too many foods and
drinks high in sugar content, causes not only tooth
decay [6] but also weight gain [7] leading to subsequent
overweight and obesity related morbidities. A recent re-
port from the United Kingdom (UK) [8] proposed the
following multifaceted approach in order to decrease
calorific consumption from sugars.
a) A gradual reduction of sugar content in everyday
food and drink products, combined with reductions
in portion size.
b) Price increases of a minimum of 10–20% on high
sugar products through the use of a tax or levy such
as on full sugar soft drinks [9].
c) Reduction in price promotions in all retail outlets
including supermarkets, stores, restaurants and
takeaways.
d) Reduction in advertisements for high sugar food and
drink products to children and adults.
e) Implementation of public sector catering standards
to ensure provision and sale of healthier food and
drinks in hospitals, leisure centers etc.f ) Encourage health promotion by providing practical
steps to help individuals lower their own and their
families’ sugar intake.
Just as in other developed and developing countries,
Israelis are not immune from being overweight or obese
and their related morbidities [10].
This paper is a response to the request of the Minister
of Health, to provide an estimate as to the potential re-
duction in mortality, morbidity and health care costs if a
national program (containing many elements similar to
that proposed in the UK [8]), but with the addition of la-
belling of products with high sugar content [11], to re-
duce calorific intake from sugar consumption is adopted
and implemented in Israel.
Methods
Prevalence
Estimates of the gender, religion (Jews and non-Jews)
and age-specific (20–64, 65+) measured prevalence rates
of overweight and obesity in Israel in 2016, were based
on extrapolations and interpolations of data from a
number of national surveys on self-reported [12–14] and
measured [15, 16] rates of overweight and obesity.
Relative risks
Cause and gender-specific data on relative risks (along
with 95% Confidence Intervals) for 16 diagnoses were
obtained from a Canadian cost of illness study based on
meta-analyses [17] and from a more recent meta-
analyses for type II diabetes [18], non-alcoholic fatty
liver disease [19] and gout [20], the latter two diagnosis
specific risks being based on average BMI levels of 27.3
and 33.6 in Israeli overweight and obese persons respect-
ively [21].
Population attributable fraction (PAF)
The gender and diagnosis specific PAF, were calculated,
for both the prevalence of overweight and obesity in
turn using the following standard formula:-
PAF ¼ prevalence  RR – 1ð Þ
prevalence  RR−1ð Þ þ 1½ 
The resultant PAF were then aggregated across gen-
ders and combined for overweight and obesity in order
to arrive at a composite diagnosis specific PAF.
Hospital expenditures
Age, gender and cause specific data on days hospitalization
in general hospitals for persons over 20 in 2016 were esti-
mated by applying the average age, gender and cause spe-
cific hospitalization rates in persons aged 20+ from 2010 to
2013 (Personal communication, Tziona Haklaii and
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Division) to the age and gender specific population data for
2016, which in turn was based on extrapolations of data
from 2013 to 2015 [22–24]. Total general hospital costs for
diseases associated with overweight and obesity were calcu-
lated by multiplying the disease specific utilisation data by
the per day costs (2127–2613 NIS) associated with their re-
spective departments [25] and the disease specific utilization
of intensive care units costing around 5852 NIS per day
[26]. The resultant figure was then multiplied by a factor of
1.33 [23] to take into account utilisation of geriatric hospi-
tals, rehabilitation and convalescent facilities as well as asso-
ciated research costs (which are an integral part of
providing quality medical care in hospitals).
Direct health expenditures
Cause specific costs of out of hospital pharmaceutical
use and other services (eg; ambulatory, emergency room,
out- patient visits etc.) were estimated by applying cost
ratios from a Canadian study [17] to the Israeli based
hospital expenditures
Total Direct Costs ¼
Hospital Costs þ Out of Hospital Pharmaceutical Costs
þ Other service Costs
Productivity losses and other indirect costs
Estimates of indirect costs included mainly productivity
losses, due to increased absenteeism and presenteeism (i.e.
workers coming in to work, but with impaired productivity
due to their health condition), in addition to informal carers
costs and transport costs. Imputed human capital costs from
premature mortality were excluded as these are in effect
“virtual” costs, but frictional employment costs (i.e.; retrain-
ing substitute workers to replace the deceased worker) were
included. Estimates of the ratio of indirect costs relative to
health service costs were based on international published
literature [17, 27–41], where information was available that
enabled distinction between human capital valuations of
mortality and other indirect costs. This ratio was then multi-
plied by the calculated direct health services costs in order
to provide cause specific estimates for indirect costs result-
ing from overweight and obesity. Since categorizations of in-
direct costs are not always homogeneous, we used a
sensitivity analysis based on the semi-interquartile range for
confidence limits around our median estimate.




The disease-specific product of these expenditures and
PAF estimated the various cost of these diseases.Dental fillings
Israelis consume on average 22.9 kg per capita (62.7 g. per
day) of sugar annually [23], this provides 12.45% of all cal-
orific intake in Israel [23] similar to the figure of 12.06% in
the UK [7]. A cross-section of international data [42], en-
abled the calculation of the prevalence of caries attribut-
able to sugar, based on regression coefficient slopes of
0.02 (intercept of no sugar consumption estimates 2.13
caries) in milk teeth (in persons aged 6.5 years old) and
0.04 (intercept of 0.06) caries per gm. per person per day
in adult teeth (in persons aged 12.5 years old), This figure
was then divided by the amount of sugar consumed by the
two groups in order to estimate the annual caries inci-
dence per exposed tooth year attributable to sugar con-
sumption and other causes in Israel. In keeping with
guidelines from the UK, we only included the impact of
sugar consumption and changes in the incidence of dental
caries in children and young adults (under 18 years of
age), because the development of dental caries depends on
life-long exposure to risk factors [43].
The following formula was used for milk and adult
teeth in turn, aggregated up to 18 years old:-
Incidence of caries ¼ Incidence per tooth year
 number of tooth years in population
 100% − % decrease due to fluoridationð Þ
Assuming fluoride in the water supply reduces caries
by 35.5% (95% CI 25.7–45.3%) in milk teeth and 26.4%
(95% CI 16.4–36.6%) in adult teeth [44].
Cost of fillings
Cost of fillings were based on sick fund specific costs (ran-
ging from 162 to 193 NIS for a single surface and 253–596
NIS for multiple surfaces) in proportion to their member-
ship [45] and private dental costs (150–600 NIS), assuming
40% were carried out by independent private dentists.
Mortality
Gender and cause specific data on mortality for persons over
twenty years old in 2016 were estimated by applying the
average age, gender and cause specific mortality rates in per-
sons aged 20+ from 2009 to 2013 (Personal communication,
Tziona Haklaii and Nehama Goldberger of the Health Min-
istry’s Information Division) to the aforementioned age and
gender specific population data for 2016 [22–24].
These cause and gender specific deaths were then
multiplied by the cause and gender specific PAFs in
order to estimate the number of deaths attributable to
overweight and obesity in 2016.
Potential Years of Life Lost (PYLL)
Extrapolations of age and gender specific life expectancies
to 2016 [22, 23] were multiplied by age-gender and cause




Jewish males 32.7% 21.9%
Jewish females 23.2% 19.5%
Non-Jewish males 32.5% 24.1%
Non-Jewish females 27.3% 29.6%
65+
Jewish males 43.5% 31.2%
Jewish females 30.8% 27.8%
Non-Jewish males 43.2% 34.3%
Non-Jewish females 36.2% 42.2%
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cific PYLL attributable to overweight and obesity.
Disability Adjusted Life Years (DALY)
Age- and gender-specific disability weights, used by the
Ministry of Health, were applied to the life expectancies in
2016 [22, 23] in order to calculate the age and gender spe-
cific Healthy Adjusted Life Expectancy (HALE), subject to
a 3% per annum discount rate. These HALEs were subse-
quently multiplied by the age-gender and cause specific
mortality data from 2010 to 2013 (Personal communica-
tion, Tziona Haklaii and Nehama Goldberger of the
Health Ministry’s Information Division) in order to calcu-
late the cause specific DALY loss due to mortality.
DALY loss due to morbidity
Due to lack of cause specific disability weights, we as-
sumed that each days hospitalization resulted in a dis-
ability weight of 0.3 (varied using a sensitivity analysis
between 0.2 and 0.4), which was then multiplied by the
age-and gender specific hospitalization rates adjusted by
the Ministry of Health’s age- and gender-specific disabil-
ity weights of health people in order to estimate the
DALY losses due to morbidity.
Sugar reduction
Data from a recent UK modelling study [8] was used to
estimate the effect on mortality, morbidity and costs of
reducing calorific consumption of sugar from 12.45 to
10% in 5 years (a feasible short-term goal) or to 5% in
fifteen years (a harder to attain long-term goal) by
means of a multi-faceted National program.
Cost utility analysis
The basic formulae used for calculating the cost per
averted DALY loss is:-
Cost per averted DALY loss
¼ Cost of intervention – Tax revenues − Savings in costs
Averted DALY losses
where:-
From the health services perspective:
Savings in costs ¼ Reduction in direct treatment costs
From the Societal perspective:
Savings in costs ¼ Reduction in ðdirect treatment
þ productivity losses þ other indirect costsÞ:
Averted DALY losses ¼ Averted DALY losses due
to morbidity and mortality decreases:
All costs are presented in new Israeli shekels (NIS) at
2016 price levels. (at an exchange rate of 3.86 NIS toUS dollar). Israel has no official policy guidelines for
defining whether or not a health intervention is cost-
effective. Affordability of interventions is a function of
the amount of resources available in a country as prox-
ied by its Gross Domestic Product (GDP) per capita.
Therefore, WHO guidelines were used, which define an
intervention as being very cost-effective [46] if the cost
per DALY averted is less than the GDP per capita of
136,907 NIS ($35,427) in Israel [22–24, 47].
Estimated sugar tax revenues were based on recent
UK estimates of 520,000,000 lb sterling per annum from
just taxing soft drinks [48] adjusted for differences in
population size and GNP per capita.
Results
Table 1 shows the high estimated prevalence of over-
weight and obesity in 2016 for both genders aged 20–64
and the even higher prevalence in the over 65 s, especially
amongst non-Jewish females. There are around 2,056,000
overweight and 1,719,000 obese adults in Israel.
Disease specific relative risks for overweight and obesity
are especially elevated for type II diabetes (both genders),
pulmonary embolisms (both genders), osteoarthritis
(males) and coronary arterial disease (females) (Table 2).
Estimated direct costs of comorbidities related to over-
weight and obesity in Israelis aged over 20 years old
were around 4763 million NIS of which hospital care
accounted for 44.8% and pharmaceutical consumption
outside of hospitalization 24.2% (Appendix 1).
Since the PAF for Type II Diabetes exceeded 100%,
we constrained its PAF to be an arbitrary 90%.
Around 6402 people (95% CI 3296–8760) died in
2016 (Table 3) as a result of conditions associated
with them being overweight (2315 deaths: 95% CI
695–3535) or obese (4086 deaths: 95% CI: 2600–
5225). The leading causes of death were Coronary Ar-
tery Disease which accounted for 2207 (95% CI:
1763–2649) fatalities (34.5% of all attributable deaths),
Table 2 Disease-specific relative risks for overweight and obese
persons by gender
Overweight Obese Ref.
Male Female Male Female
Asthma 1.20 1.25 1.43 1.78 [14]
Breast cancer 1.00 1.08 1.00 1.13 [14]
Congestive heart failure 1.31 1.27 1.79 1.78 [14]
Colorectal cancer 1.51 1.45 1.95 1.66 [14]
Coronary artery disease 1.29 1.80 1.72 3.10 [14]
Diabetes type II 2.20 3.60 6.05 11.15 [14, 15]
Endometrial cancer na 1.53 na 3.22 [14]
Gallbladder disease 1.09 1.44 1.43 2.32 [14]
Gout 2.02 1.79 3.70 2.95 [20]
Hypertension 1.28 1.65 1.84 2.42 [14]
Kidney cancer 1.40 1.82 1.82 2.64 [14]
Non-alcoholic fatty liver 1.30 1.52 4.09 4.78 [19]
Esophageal cancer 1.13 1.15 1.21 1.20 [14]
Osteoarthritis 2.76 1.80 4.20 1.96 [14]
Ovarian cancer na 1.18 na 1.28 [14]
Pancreatic cancer 1.28 1.24 2.29 1.60 [14]
Prostate cancer 1.14 1.00 1.05 1.00 [14]
Pulmonary embolism 1.91 1.91 3.51 3.51 [14]
Stroke 1.23 1.15 1.51 1.49 [14]
Table 3 Deaths attributable to overweight or obesity in adults over
Deaths Attributable to obesity or overweig
Coronary artery disease 4949 2207
Diabetes type II 941 847
Congestive heart failure 2279 822
Stroke 2742 671
Colorectal cancer 1456 609
Hypertension 846 399
Pancreatic cancer 938 344
Pulmonary embolism 144 111
Kidney cancer 232 110
Breast cancer 1111 78
Endometrial cancer 92 55
Ovarian cancer 292 43
Prostate cancer 394 35
Asthma 116 32
Esophageal cancer 143 18
Gallbladder disease 30 10
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(12.8%), Stroke (10.5%) and Colorectal Cancer (9.5%).
Each fatality lost an average of 12.4 years (PYLL) or 7.1
(discounted) years of HALE, with an average associated
disability weight (DW) of 0.43, which reflects the high per-
centage of deaths in the 75–84 (25%) and 85+ age groups
(41%) when functional deterioration has set in even
amongst healthy persons.
Around 268,206 (95% CI: 135,362–354,252) hospital
days were attributable to Overweight (98,545) and Obes-
ity (169,464), accounting for 16.1% (95% CI: 4.5–23.7%)
and 27.6% (95% CI: 17.5–34.0%) respectively of the
612,844 hospital days associated with related diagnoses
(Appendix 2).
Coronary Artery Disease (21.5%) Type II diabetes
(21.1%), and Hypertension (20.4%) account for over
three-fifths of the 2185 (95% CI: 878–2667) million NIS
direct costs (Table 4) related to overweight (802 million
NIS : 95% CI 51–1122 million NIS) and obesity (1383
million NIS : 95% CI 827–1545 million NIS).
The ratio of indirect to health service costs from
the literature had a median value of 72.2% (semi-
interquartile range 44.7–130.0%), giving an estimate
of 1578 (95% CI: 977–2841) million NIS for the indir-
ect costs. Therefore, the total costs to society attribut-
able to overweight (1381: 95% CI 74–2581 million20 years old by diagnosis (2016)





















Table 4 PAF and direct costs (NIS) attributable to overweight and obesity by diagnoses - Israeli adults (2016)
PAF overweight PAF obesity Total cost Attributable to overweight
& obesity
Coronary artery disease 16.1% 28.5% 1,055,915,767 470,784,150 21.5%
Diabetes type II 33.5% 56.5% 511,313,763 460,182,387 21.1%
Hypertension 16.8% 30.4% 943,186,656 445,157,136 20.4%
Congestive heart failure 12.1% 24.0% 462,954,791 166,984,682 7.6%
Osteoarthritis 31.1% 35.8% 247,895,278 165,852,084 7.6%
Stroke 8.2% 16.3% 490,337,015 119,962,933 5.5%
Colorectal cancer 18.0% 23.8% 220,788,825 92,322,002 4.2%
Pulmonary embolism 28.2% 48.6% 93,633,779 71,915,718 3.3%
Asthma 8.4% 19.1% 260,546,602 71,698,574 3.3%
Gallbladder disease 9.4% 23.7% 115,622,301 38,181,949 1.7%
Kidney cancer 19.1% 28.5% 46,068,752 21,944,698 1.0%
Pancreatic cancer 10.6% 26.1% 52,536,885 19,257,766 0.9%
Endometrial cancer 16.3% 44.2% 28,576,252 17,298,101 0.8%
Breast cancer 2.8% 4.3% 124,719,472 8,786,692 0.4%
Prostate cancer 6.9% 2.0% 49,259,925 4,358,259 0.2%
Ovarian cancer 6.0% 8.8% 28,750,951 4,263,974 0.2%
Esophageal cancer 5.7% 7.0% 23,724,293 3,015,682 0.1%
Non-alcoholic fatty liver 14.6% 22.4% 4,413,971 1,633,711 0.1%
Gout 31.4% 16.1% 3,409,277 1,618,618 0.1%
Total 6,512,219,714 2,185,219,115 100.0%
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NIS), amount to around 3763 (95% CI: 3163–5027)
million NIS annually.
The estimate of caries prevalence per person attrib-
utable to sugar consumption was 1.25 (in children
aged 6.5 years) and 2.51 (in children aged 12.5 years).
This translates into an annual per capita caries inci-
dence attributable to sugar of 0.21 for milk teeth and
0.39 for adult teeth respectively (Appendix 3). There
is an estimated need for 1.67 million fillings annually
in persons under 18 years old, costing around 374
million NIS (at an average cost of 224 NIS per fill-
ing). Sugar consumption was estimated to account for
around 70.6% of all caries (and hence potential fill-
ings) in this age group, at a cost of around 264 mil-
lion NIS annually in Israel.
Hence, the direct and societal costs attributable to
obesity, overweight and sugar consumption are 2449
million and 4027 million NIS respectively (both costs
including 264 million caries costs attributable to sugar
consumption), representing 0.21 and 0.35% of GDP
respectively.
Discussion
In contrast to deaths which are clearly attributable to a
given causality (such as motor vehicle collisions,suicides, falls, fires, drowning etc..), deaths due to pollu-
tion and to personal behaviours, such as smoking,
sedentariness and nutritional habits are harder to
identify. Despite this difficulty, obesity and overweight
have been implicated as risk factors for many causes
of death [17, 49, 50].
The estimate of 6402 deaths annually attributable to
overweight and obesity (around 15% of all deaths) is
over 17 times the magnitude of suicides, 18 times
that of road accident fatalities and around 50 times
that of homicides in Israel [23]. The direct cost of
treating morbidity from overweight and obesity, is
around 2.18 billion NIS, equivalent to 0.19% (95% CI:
0.08–0.23%) of Israel’s GDP [23, 24] or 2.5% (95% CI:
1.0–3.9%) of all health expenditures. This represents
an average annual cost of 391 NIS and 802 NIS re-
spectively, for each obese or overweight Israeli aged
20 and over.
The total costs to society of treating morbidity from
obesity and overweight, is around 3.8 billion NIS,
equivalent to 0.32% (95% CI: 0.27–0.43%) of GDP.
[17, 18], an average annual expenditure of 674 NIS
and 1381 NIS respectively for each obese or over-
weight Israeli aged 20 and over. Due to the high bur-
den of disease, introduction of programs to reduce
sugar consumption are desirable.
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An as yet undefined, national program of reducing en-
ergy from sugar consumption from its current level of
12.45 to 10% will reduce damage from sugar related
obesity (and overweight) by 3.7% over a five year time
horizon [7] and reduce caries by 16.1%. This will annu-
ally, on average, prevent 237 (95% CI: 112–325) deaths,
9917 days hospitalization and around 180,000 fillings
(Table 5). This will result in annual savings of direct
treatment costs of around 121 million NIS (including 40
million NIS from caries reduction) and total societal
costs of 180 million (95% CI: 118–294 million) NIS or
0.02% (95% CI: 0.01–0.03%) of GDP (Table 5).
If a more ambitious target of reducing consumption to
5% is achieved over a 15 year period, sugar related obes-
ity (and overweight) will decrease by 7.7% [7] and caries
by 49.1%. This means that annually an average of 494
(95% CI: 254–677) deaths, 20,699 days hospitalization
and 336,000 fillings will be prevented, resulting in sav-
ings of around 244 million NIS in direct costs (including
75 million NIS in caries reduction) and societal costs of
366 million (95% CI: 239–605 million) or 0.03% (95%
CI: 0.02–0.05%) of GDP.Table 5 Average annual mortality, morbidity decreases and cost sav
10% of energy from sugar in 5 years
Averted:-
Deaths 237




Overweight & obesity treatment 80,854,527
Total direct costs (NIS): 121,130,829
Indirect costs 58,375,715
Total societal costs (NIS) 179,506,544
% of per capita GDP 0.02%
5% of energy from sugar in 15 years
Averted:-
Deaths 494




Overweight & obesity treatment 168,767,366
Total direct costs (NIS): 244,215,145
Indirect costs 121,847,423
Total Societal Costs (NIS) 366,062,568
% of per capita GDP 0.03%Cost utility analysis of reducing sugar consumption
Assuming the imposition of an intervention program
will succeed in reducing energy consumption from sugar
to 10% over 5 years, there will be a saving of 1184 lives
and 14,703 PYLL, giving a total of 8425 averted
discounted DALYS. Since 99.7% of these DALYS are due
to mortality gains, varying the disability weight of
hospitalization between 0.2 and 0.4 will have an insig-
nificant effect on the results.
Imposing a tax on sugar products could be part of
the multifaceted approach to reducing sugar con-
sumption. Taxing soft drinks could annually generate
around 280 million NIS of income (based on adjusted
UK estimates). In the UK such revenues are ear-
marked to improve primary school sports facilities. In
Israel, around 24 million NIS of the revenues annu-
ally could be earmarked to add 100 full time equiva-
lent dietician posts (including office facilities) to help
implement other parts of the multifaceted program to
reduce sugar consumption. Over 5 years this hypo-
thetical intervention will for an intervention cost of
around 120 million NIS, generate 1400 million in tax
revenues, save 606 million NIS in direct treatmentings (NIS) by sugar consumption goals
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resulting in a net (cost-) saving of 2178 million NIS.
However, the Health Minister is reluctant to impose
a sugar tax, on the grounds that such a tax will raise
consumer prices in a regressive fashion [11]. In this
scenario, the intervention will still be cost saving to
the tune of 778 million NIS. While any future impos-
ition of a sugar tax will impose only a small legisla-
tive cost, lessons should be learned from the recent
experience in New York of the practical problems of
imposing such a tax, especially in that it should be
based on a per calorie as opposed to per volume
formula [50].
These estimates, of damage from sugar consumption,
should be regarded as preliminary as they can be im-
proved upon if the following data ever becomes
available:
i) Israeli-based cause and age-specific relative risks,
thus allowing calculation of PAF due to obesity and
overweight in Israel.
ii) Israeli based disease specific costs and utilization
rates of geriatric hospitals, out of hospital
pharmaceutical and other care costs (home
helps, physiotherapy, ambulatory doctor visits
etc.).
iii) Israeli-based cause specific estimates of work
productivity losses and other indirect costs.
iv) Estimates of disability weights relating to
morbidity in an out-of hospital setting. This
would correct for the underestimation of DALYS
averted (and subsequent overestimation of Costs
per DALY averted) since only estimates for mor-
bidity losses during the period of hospitalisation
were included in the model.
Gains from reduced caries might also be overesti-
mated to the extent that some people in Israel are
already exposed to fluoride via toothpaste and their
natural water supplies. On the other hand, estimates of
the costs of treating caries and hence potential savings
attributable to reductions in sugar consumption can be
considered as being very conservative as they do not in-
clude any costs incurred by persons aged 18 years and
over, who will almost certainly benefit from a reduction
in sugar consumption [51].
Further underestimations of averted DALYS and
averted treatment costs arose because the model was
based solely on the relative risks of overweight and
obese persons and was unable (because of lack of
data) to take into account the impact of reductions
in sugar consumption in persons of normal weight.
For example, many new onset cases of type II dia-
betes occur in persons of normal anthropometricproportions who would also benefit from reduction
in sugar consumption [52].
All the estimates are subject to the important cav-
eat that any achieved calorific reduction due to de-
creased sugar consumption is not compensated for
by increased calorific intake of other (non-sugar)
foods. But even in the event that a compensating
rise in calorific consumption occurs (resulting pos-
sibly in an isocaloric situation), some health benefits
are likely to still be generated as “not all calories are
equal” since there is evidence that the quality of fat
and carbohydrate can play a more important role
than the quantity [53]. The resultant diet that is
lower in sugar (carbohydrates) is likely be healthier
than the initial high in sugar diet, especially with re-
spect to type II diabetes risk factors in young people
[54]. If full calorific compensation occurs, then the
mortality and morbidity gains estimated in this paper
will be around 74% lower [55], resulting in there be-
ing a gain of 2190 DALYs and a net saving of only
113 million NIS in the scenario where no tax is im-
posed on sugar.
Reducing energy from sugar consumption from its
current level of 12.45 to 10%, over a five year time
horizon is considered to be a very reasonable and at-
tainable short-term goal. Over these 5 years, this
would save 2178 million NIS in costs (778 million
NIS if no taxes are imposed) as well as 1184 lives.
Achieving a reduction to 5% over a 15 year period
would be a far harder goal to achieve, but the re-
wards in terms of decreased mortality, morbidity and
expenditures would be greater.
It is highly likely that any package of interventions,
with or without the imposition of taxes on sugar, will
be cost-saving (i.e. supplying quality adjusted life years
at no additional net cost), since costs savings from mor-
bidity reductions (and possible tax revenues) will ex-
ceed the costs of the intervention. This will still be true
if we view the results just from just the direct costs of
health services perspective. Finally, it should be noted
that other many other interventions available to re-
duce overweight and obesity are available, that have
also been shown to be cost-saving or very cost
effective [21, 56].Conclusions
Sugar consumption causes a huge monetary and mor-
tality burden. Estimates of potential decreases in this
burden justify the current prioritisation given by the
health minister of creating and implementing a national
program to reduce sugar consumption, which is likely
to be cost-saving (ie: averted treatment costs will ex-
ceed intervention costs).
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Hospital care Other care Drugs excl hosp Total cost
Coronary artery disease 591,658,411 242,594,993 221,662,363 1,055,915,767 22.2%
Hypertension 61,099,650 395,143,788 486,943,218 943,186,656 19.8%
Diabetes type II 206,869,057 181,625,245 122,819,461 511,313,763 10.7%
Stroke 370,683,266 112,966,069 6,687,680 490,337,015 10.3%
Congestive heart failure 296,083,592 105,115,078 61,756,121 462,954,791 9.7%
Asthma 41,796,206 109,329,885 109,420,510 260,546,602 5.5%
Osteoarthritis 108,937,052 75,063,697 63,894,529 247,895,278 5.2%
Colorectal cancer 144,207,495 64,220,043 12,361,287 220,788,825 4.6%
Breast cancer 47,387,005 56,090,016 21,242,451 124,719,472 2.6%
Gallbladder disease 77,257,439 30,853,722 7,511,140 115,622,301 2.4%
Pulmonary embolism 52,141,557 23,642,864 17,849,358 93,633,779 2.0%
Pancreatic cancer 35,098,638 14,772,528 2,665,719 52,536,885 1.1%
Prostate cancer 22,111,658 21,229,074 5,919,193 49,259,925 1.0%
Kidney cancer 26,858,616 15,474,832 3,735,304 46,068,752 1.0%
Ovarian cancer 19,039,091 8,197,386 1,514,473 28,750,951 0.6%
Endometrial cancer 14,533,230 10,957,594 3,085,428 28,576,252 0.6%
Oesophageal cancer 16,018,731 6,573,203 1,132,359 23,724,293 0.5%
Non-alcoholic fatty liver 2,054,218 1,341,950 1,017,803 4,413,971 0.1%
Gout 1,586,644 1,036,499 786,134 3,409,277 0.1%
Total 2,135,421,555 1,476,228,468 1,152,004,532 4,763,654,555 100.0%Appendix 2Table 7 Hospital days attributable to overweight and obesity in Israeli adults (2016)
Days Overweight Obesity Normal or underweight
Coronary artery disease 169,800 27,316 48,390 94,094
Diabetes type II 59,369 19,962 33,470 5937
Congestive heart failure 84,973 10,285 20,364 54,324
Stroke 106,382 8707 17,320 80,355
Osteoarthritis 31,264 9733 11,183 10,347
Colorectal cancer 41,386 7451 9855 24,081
Pulmonary embolism 14,964 4215 7278 3471
Hypertension 17,535 2942 5334 9259
Gallbladder disease 22,172 2075 5247 14,850
Pancreatic cancer 10,073 1063 2629 6381
Kidney cancer 7708 1474 2198 4036
Asthma 11,995 1008 2293 8694
Endometrial cancer 4171 680 1844 1646
Breast cancer 13,600 375 583 12,641
Ovarian cancer 5464 329 482 4654
Esophogal cancer 4597 263 321 4013
Prostate cancer 6346 436 125 5784
Non-alcoholic fatty liver 590 86 327 177
Gout 455 143 221 91
Total 612,844 98,545 169,464 344,835
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sugar consumption in Israel
Milk teeth Adult teeth
Age of child (years)a 6.5 12.5
Caries with zero sugar (intercept)a 2.13 0.06
Caries per gm per person daya 0.02 0.04
Caries prevalence from sugarb 1.25 2.51
% of caries from sugar 37% 98%
Tooth years of exposure 94 72
Sugar consumption (Kgm)c 137 149
Caries per Kgm sugar consumption 0.009 0.017
Annual caries incidence per persond 0.21 0.39
Notes:-
abased on regressions from international cross-sectional study [36]
bbased on Israeli consumption of 62.7 g/day
cfrom 6 months to 6.5 years for milk teeth and 6.0 years to 12.5 years for
adult teeth
dattributable to sugarAbbreviations
BMI: Body Mass Index; DALY: Disability adjusted life year; GDP: Gross
Domestic Product; HALE: Healthy Adjusted Life Expectancy; NIS: New Israeli
shekel; PAF: Population attributable fraction; PYLL: Potential Years of Life Lost;
RR: Relative risk; UK: United Kingdom of Great Britain and Northern Ireland;
WHO: World Health Organization
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